Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Cerus Corporation (Nasdaq: CERS) announced a group purchasing agreement with Blood Centers of America (BCA) on December 10, 2025 covering Cerus’ entire INTERCEPT product line.
The agreement covers pathogen reduction for platelets, plasma and INTERCEPT Fibrinogen Complex (IFC), and will use a resource-sharing model to move ongoing IFC production across BCA member blood centers. BCA represents 60+ independent community blood centers that produce about half of U.S. platelet and cryoprecipitate supply. Cerus and BCA plan collaborative training and distribution to expand access and adoption of pathogen reduction technology.
Cerus (Nasdaq: CERS) reported record third-quarter 2025 results with total revenue $60.2M (+19% YoY) and product revenue $52.7M (+15% YoY). Government contract revenue was $7.5M (+63% YoY). Q3 product gross margin was 53.4% versus 56.9% a year ago. Hospital demand for INTERCEPT fibrinogen complex (IFC) volumes rose ~110% YoY; Q3 U.S. IFC sales were $3.9M.
Q3 GAAP net loss narrowed to $0.02M (near breakeven); non-GAAP adjusted EBITDA was $5.0M. Cash and short-term investments were $78.5M at Sept 30, 2025. Full-year 2025 product revenue guidance raised to $202M–$204M (12%–13% growth); IFC guidance set at $16M–$17M.
Cerus (Nasdaq: CERS) will host an industry workshop on INTERCEPT Fibrinogen Complex (IFC) at the 2025 AABB Annual Meeting in San Diego, Oct 25–28, 2025.
The workshop is scheduled for Oct 27, 2025 at 7:00 a.m. PT and features blood center and blood bank speakers; a replay will be posted on Cerus’ product site about one week after the event. Cerus will also present 18 related abstracts and exhibit at booth #1713.
Cerus Corporation (Nasdaq: CERS) will release its third quarter 2025 financial results on November 6, 2025 after market close.
The company will host a conference call and webcast on the same day at 4:30 P.M. ET to discuss results, business overview, and outlook. Investors can access the live webcast and presentation slides on Cerus’ Investor Relations website and may register to join the call; attendees are encouraged to log in 10 minutes early. A replay will be posted approximately three hours after the call and remain available through November 27, 2025.
Cerus Corporation (Nasdaq: CERS) announced a significant recommendation from the German National Blood Advisory Committee (AK Blut) advocating for pathogen inactivation (PI) measures, including INTERCEPT®, to enhance platelet transfusion safety.
The recommendation highlights that while current safeguards have reduced transfusion-transmitted bacterial infections (TTBI), risks remain with approximately 5 clinical cases per million transfusions, and potentially up to 1,300 contaminated units per million. Germany produces over 600,000 platelet doses annually, the highest in Europe.
Key recommendations include treating platelet units with PI or validated bacterial screening, extending PI-treated platelet shelf life to seven days, limiting untreated platelets to three days, and adjusting reimbursement rates to cover PI treatment costs.
Cerus Corporation (Nasdaq: CERS) announced its upcoming participation in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 10:55 A.M. ET.
Investors can access the live webcast through the Events and Presentations section on ir.cerus.com. A replay of the presentation will remain available for 30 days following the event.
Cerus Corporation (Nasdaq:CERS) reported strong Q2 2025 financial results with total revenue of $60.1 million, including record product revenue of $52.4 million, up 16% year-over-year. The company's INTERCEPT Fibrinogen Complex (IFC) revenue surged to $5.6 million from $2.0 million in the prior year.
Despite posting a net loss of $5.7 million, Cerus achieved positive non-GAAP adjusted EBITDA of $0.9 million. The company's cash position stood at $78.0 million as of June 30, 2025. Given strong performance, Cerus raised its full-year 2025 product revenue guidance to $200-203 million, with IFC revenue expected between $16-18 million.
Notable progress includes advancement in the European regulatory review of INTERCEPT Blood System for Red Blood Cells and a $7.2 million Department of Defense funding for lyophilized IFC development.
Cerus Corporation (Nasdaq: CERS) has scheduled the release of its second quarter 2025 financial results for Tuesday, August 5, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET to discuss financial results and provide business updates.
Investors can access the live webcast and presentation slides through Cerus' Investor Relations website. A replay will be available approximately three hours after the call until August 26, 2025.
Cerus Corporation (Nasdaq: CERS) has secured an additional $7.2 million contract amendment from the U.S. Department of Defense (DoD) to advance the development of lyophilized INTERCEPT Fibrinogen Complex (LyoIFC) for treating trauma-related bleeding. This supplements their existing $18 million DoD contract for developing room-temperature, shelf-stable LyoIFC.
The new funding will support the CRYO-FIRST study, a 320-patient randomized trial comparing pre-thawed IFC to conventional cryoprecipitated antihemophilic factor in trauma patients with hemorrhagic shock. The study aims to evaluate the effectiveness of early fibrinogen administration in trauma patients and will begin enrollment in early 2026.
Since receiving initial DoD funding in November 2022, Cerus has achieved key milestones including FDA pathway discussions, successful process scale-up, and prototype delivery to the DoD.
Cerus Corporation (Nasdaq: CERS) announced progress in its European regulatory review for the INTERCEPT Red Blood Cells (RBC) system. The company's Notified Body, TÜV-SÜD, has completed reviewing the clinical module of the CE Mark submission and transferred information to the Czech Republic's State Institute for Drug Control (SÚKL).
The clinical module includes positive results from the U.S. Phase 3 ReCePI trial, expanding the CE Mark submission to cover all patient indications for RBC transfusion. SÚKL will now review the API module before TÜV-SÜD conducts manufacturing facility audits for final CE Mark decision.